Study of Oral Nutritional Supplements During Concurrent Chemoradiotherapy for Local Advanced Non-small...
Local Advanced Non-small Cell Lung CancerThis Phase II randomized study is to determine the efficacy of oral nutritional supplements(ONS) during concurrent chemoradiotherapy for local advanced non-small cell lung cancer, and discuss when to deliver ONS and which indicator should be the goal of ONS.
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along...
CarcinomaNon-small Cell Lung Cancer1 moreThis is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-generation EGFR-TKIs resistance along with T790M negative.
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small...
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIA1 moreThe main purpose of this study is to evaluate the relapse free survival of patients who have EGFR-mutant stage IIIA-IIIB Non-small Cell Lung Cancer and receive Icotinib as consolidation therapy after synchronous or sequential chemoradiotherapy.
Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid
Non-small-Cell Lung CancerThe purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.
A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC)...
Non-small Cell Lung Cancer (NSCLC)This is a prospective, randomized, multicenter clinical study designed to evaluate its safety and efficacy by using Docetaxel with or without Traditional Chinese Medicine XH1 in patients with Stage ⅢB-Ⅳ Non-small Cell Lung Cancer (NSCLC) who failed with first-line Chemotherapy. The primary outcome measure includes progression-free survival (PFS) after treatment. Secondary outcome measures include collecting biomarkers before and during treatment, overall survival (OS), objective response rate (ORR), disease control rate (DCR), and patient's quality of life.
Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Non-small Cell Lung CancerThis is a Phase 1B study designed to assess the safety and tolerability of LYC-55716 given in combination with pembrolizumab to subjects with metastatic NSCLC, and to assess the combination for biologic and clinical activity in NSCLC.
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment...
Non Small Cell Lung Cancer Stage IIIBNon-Small Cell Carcinoma of Lung1 moreInternational multi-center open-label randomized clinical trial of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) monotherapy compared to docetaxel as second-line therapy of patients with advanced inoperable or metastatic non-small cell lung cancer
Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors
Lung CancerLung Cancer Metastatic2 moreThe feasibility of a RF ablation catheter to bronchoscopically ablate lung tumors, will be evaluated in patients already scheduled for surgical resection.
Personalized DC Vaccine for Lung Cancer
CarcinomaNon-Small-Cell LungThe study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
Non-squamous Non-small-cell Lung CancerThis trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer.